Contrasting of Exelixis Inc. (EXEL) and Albireo Pharma Inc. (NASDAQ:ALBO)

Both Exelixis Inc. (NASDAQ:EXEL) and Albireo Pharma Inc. (NASDAQ:ALBO) are Biotechnology companies, competing one another. We will compare their risk, analyst recommendations, profitability, dividends, earnings and valuation, institutional ownership.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Exelixis Inc. 745.30M 8.42 368.47M 1.18 18.13
Albireo Pharma Inc. 12.17M 25.04 35.30M -3.01 0.00

Table 1 shows gross revenue, earnings per share and valuation of the two companies.

Profitability

Table 2 provides us the return on assets, return on equity and net margins of both businesses.

Net Margins Return on Equity Return on Assets
Exelixis Inc. 49.44% 55.7% 43.8%
Albireo Pharma Inc. -290.06% 0% 0%

Volatility & Risk

Exelixis Inc. has a 2.3 beta, while its volatility is 130.00% which is more volatile than S&P 500. Albireo Pharma Inc. has a 1.78 beta and it is 78.00% more volatile than S&P 500.

Liquidity

The Current Ratio and a Quick Ratio of Exelixis Inc. are 8.7 and 8.5. Competitively, Albireo Pharma Inc. has 19.4 and 19.4 for Current and Quick Ratio. Albireo Pharma Inc.’s better ability to pay short and long-term obligations than Exelixis Inc.

Analyst Recommendations

The table delivered features the ratings and recommendations for Exelixis Inc. and Albireo Pharma Inc.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Exelixis Inc. 1 1 0 2.50
Albireo Pharma Inc. 0 0 0 0.00

Exelixis Inc.’s average price target is $20.5, while its potential downside is -2.29%.

Insider and Institutional Ownership

Exelixis Inc. and Albireo Pharma Inc. has shares held by institutional investors as follows: 79.2% and 83%. Insiders held roughly 0.9% of Exelixis Inc.’s shares. Comparatively, insiders own roughly 0.5% of Albireo Pharma Inc.’s shares.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Exelixis Inc. 5.17% 23.4% 13.62% 11.66% -20.59% -29.74%
Albireo Pharma Inc. -4.16% -8.75% -23.37% -22.26% 1.77% -0.98%

For the past year Albireo Pharma Inc. has weaker performance than Exelixis Inc.

Summary

On 9 of the 12 factors Exelixis Inc. beats Albireo Pharma Inc.

Exelixis, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of new medicines with the potential to enhance care and outcomes for people with cancer. The companyÂ’s products include CABOMETYX for the treatment of patients with advanced renal cell carcinoma, who have received prior anti-angiogenic therapy; and COMETRIQ for the treatment of patients with progressive, metastatic medullary thyroid carcinoma. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors, which has shown clinical anti-tumor activity in approximately 20 forms of cancer and is the subject of a broad clinical development program. It also offers COTELLIC (cobimetinib), a selective inhibitor of MEK, in combination with vemurafenib for the treatment of patients with BRAF V600E or V600K mutation-positive advanced melanoma in the United States; and in combination with vemurafenib in other territories, including the European Union, Switzerland, Canada, Australia, and Brazil. Exelixis, Inc. has collaboration and license agreements with Ipsen Pharma SAS, Genentech, Inc., GlaxoSmithKline, Bristol-Myers Squibb Company, Sanofi, Merck, and Daiichi Sankyo Company Limited for the development and commercialization of various compounds and programs. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was founded in 1994 and is headquartered in South San Francisco, California.

Albireo Pharma, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and gastrointestinal (GI) disorders in the United States. Its lead product candidate includes A4250, an orally administered ileal sodium dependent bile acid transporter (IBAT) inhibitor that is in phase II clinical trial for treating progressive familial intrahepatic cholestasis and primary biliary cholangitis. The companyÂ’s clinical-stage product candidates comprise Elobixibat, an orally administered IBAT inhibitor, which is in Phase III clinical trial for the treatment of chronic constipation and other GI diseases; and A3384, a development stage product to treat bile acid malabsorption. It has license agreement with EA Pharma for the development and commercialization of elobixibat. Albireo Pharma, Inc. is headquartered in Boston, Massachusetts.